Myron G. Best 1 , 2 , Nik Sol 3 , Irsan Kooi 4 , Jihane Tannous 5 , Bart A. Westerman 2 , François Rustenburg 1 , 2 , Pepijn Schellen 2 , 6 , Heleen Verschueren 2 , 6 , Edward Post 2 , 6 , Jan Koster 7 , Bauke Ylstra 1 , Najim Ameziane 4 , Josephine Dorsman 4 , Egbert F. Smit 8 , Henk M. Verheul 9 , David P. Noske 2 , Jaap C. Reijneveld 3 , R. Jonas A. Nilsson 2 , 6 , 10 , Bakhos A. Tannous 5 , 12 , Pieter Wesseling 1 , 11 , 12 , Thomas Wurdinger 2 , 5 , 6 , 12 , ∗
09 November 2015
Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based “liquid biopsies”.
Tumors “educate” platelets (TEPs) by altering the platelet RNA profile
TEPs provide a RNA biosource for pan-cancer, multiclass, and companion diagnostics
TEP-based liquid biopsies may guide clinical diagnostics and therapy selection
A total of 100–500 pg of total platelet RNA is sufficient for TEP-based diagnostics
Best et al. show that mRNA sequencing of tumor-educated blood platelets distinguishes cancer patients from healthy individuals with 96% accuracy, differentiates between six primary tumor types of patients with 71% accuracy, and identifies several genetic alterations found in tumors.